Programmable Bacteria for Colorectal Cancer Screening and Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for colorectal cancer (CRC) screening are invasive, costly, and have low patient adherence due to inconvenience and variable sensitivity levels of non-invasive stool-based tests. Additionally, existing therapies for CRC are often ineffective, especially for microsatellite stable CRC (MSS-CRC).
Innovation Solution
The use of programmable bacterial cells, such as Escherichia coli Nissle 1917 (EcN), that can colonize colorectal tumors and produce diagnostic and therapeutic molecules. These cells include specific nucleic acids encoding enzymes and therapeutic agents, allowing them to multiply within the tumor microenvironment and produce analytes like salicylate or butyrate, which can be detected in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If colonoscopy is used for CRC screening, then detection accuracy is improved, but patient convenience and accessibility deteriorate due to bowel preparation requirements and procedural invasiveness
Solution Approach 1:
The patent introduces an intermediary substance (engineered bacteria or their metabolic byproducts) that mediates between the patient's tumor and the detection system. The bacteria colonize tumors and produce detectable metabolites, serving as a bridge that enables non-invasive detection while maintaining high accuracy, thus resolving the contradiction between detection precision and patient convenience
Solution Approach 2:
The patent replaces the mechanical/invasive colonoscopy procedure with a biochemical detection system. Instead of physically examining the colon with a scope, the system uses engineered bacteria that metabolically interact with tumor cells and produce detectable chemical signals in stool or urine, substituting mechanical intervention with biochemical processes
2Ease of operation
If stool-based tests are used for CRC screening, then patient convenience is improved, but detection sensitivity deteriorates with variable sensitivity levels (5-40%) for pre-cancerous polyps
Solution Approach 1:
The patent fundamentally changes the detection parameter from general stool characteristics to specific bacterial metabolite concentrations. By engineering bacteria to produce unique metabolic byproducts (such as modified bile acids or specific volatile organic compounds) that result from tumor-bacteria interactions, the system transforms stool testing from a low-sensitivity general screen to a high-sensitivity specific detection method
Solution Approach 2:
The engineered bacteria perform self-service by autonomously colonizing tumors, metabolically interacting with cancer cells, and producing detectable signals. This eliminates the need for complex external processing or invasive procedures, maintaining patient convenience while achieving high sensitivity through the bacteria's intrinsic metabolic functions
3Adaptability or versatility
If conventional therapies are used for MSS-CRC, then treatment options are limited, but patient response deteriorates due to lack of immune cell infiltration making immunotherapy ineffective
Solution Approach 1:
The engineered bacteria serve as an intermediary that actively recruits and activates immune cells to the tumor microenvironment. The bacteria produce immunomodulatory metabolites or antigens that attract immune cells, thereby bridging the gap in MSS-CRC cases where immune infiltration is naturally absent, enabling immunotherapy to become effective
Solution Approach 2:
The patent applies preliminary action by using engineered bacteria to pre-condition the tumor microenvironment before conventional immunotherapy is administered. The bacteria first establish colonization, produce immunostimulatory signals, and recruit immune cells to create a receptive environment, thereby priming the tumor for subsequent immunotherapy intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The programmable bacterial cells enable non-invasive detection of colorectal tumors through analyte detection in stool or urine and can treat tumors by delivering therapeutic agents, such as antibodies and cytokines, directly to the tumor site, potentially reducing tumor burden and modifying the tumor-immune microenvironment.
Implementation Method 1
the programmable bacterial cells multiply within the colorectal tumor microenvironment (TME)
Implementation Method 2
the programmable bacterial cells produce an analyte (salicylate or butyrate), which is detectable in a biological sample
Data Source
AI summary
Orally-deliverable programmable bacteria cells that colonize colorectal tumors and produce diagnostic and therapeutic molecules, as well as related compositions and methods.